Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Pharmgate Animal Health is teaming up with Devenish Nutrition to bring pharmaceutical products to the US poultry industry.
Zoetis and Elanco have both recently received approval for poultry products in the US.
Boehringer Ingelheim has launched Semintra, which is the first oral solution to deal with feline hypertension.
Bulgarian business Huvepharma has hit the M&A trail again and purchased the animal health business of French feed firm Neovia for an undisclosed fee.
CannPal Animal Therapeutics has commenced the next phase of a pharmacokinetic and safety study for a cannabis-derived veterinary medicine to be used in pain control in dogs.
Newly-established biotechnology firm Motega Health has launched an oral-mucosal sustained delivery product to aid drug absorption across multiple species.
The US FDA has issued a warning to pet owners and consumers not to use drug and homeopathic drug products manufactured by King Bio due to high contamination levels.
ECO Animal Health has gained a new marketing authorization in Vietnam for the use of its Aivlosin antimicrobial treatment in pigs and poultry.
The co-founder and chief scientific officer of Australian firm Anatara Lifesciences has announced her departure to pursue a new humanitarian path using the firm's technology.
This year saw the 10th annual Kansas City Animal Health Investment Forum host a wide array of companies yearning to innovate and disrupt the animal health market. Animal Pharm analyst Daniel Willis gives an overview of the start-ups on display.
Canadian firm NovaVive has signed a marketing services agreement with AABEX Animal Health for the US.
Covenant Animal Health Partners has been launched to focus on bringing animal health innovations to market.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.